Press Release


The Commercialization of Asia's First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough
Mar 27, 2024 21:46 JST
In 2023, CanSinoBIO's meningococcal conjugate vaccine achieved revenue approximately RMB561.72 million, representing a year-on-year increase of approximately 266.39% compared to last year. The growth trend is evident.
More info..

Latest Release


More Latest Release >>